Elderly patients with acute coronary syndromes: Higher risk and greater benefit from antiplatelet therapy and/or interventional therapies

American Journal of Geriatric Cardiology

Volumn 12, Issue 4, 2003, Pages 259-262

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FIBRINOLYTIC THERAPY; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION; META ANALYSIS; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY;

EID: 0141989877     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2003.02012.x     Document Type: Conference Paper

References (15)

1. Aguirre FV, McMahon RP, Mueller H, et al. Impact of age on clinical outcome and postlytic management strategies in patients treated with thrombolytic therapy: Results from the TIMI II study. Circulation. 1994;90:78-86.
2. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for occluded coronary arteries trial. Circulation. 1996;94:1826-1833.
3. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031-2037.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Unstable Angina). Available at: http://www.acc.org.clinical/guidelines/unstable/update_index.htm. Accessed March 15, 2002.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
6. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet. 1996;348:1329-1339.
7. The PURSUIT Trial Investigators. Inhibition of Platelet Glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
8. The Platelet Receptor Inhibition For Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
9. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. (PRISM-PLUS) Trial Investigators. Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor With Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. N Engl J Med. 1998;338:1488-1497.
10. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
11. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708-715.
12. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol. 1995;26:1643-1650.
13. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
14. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605-613.
15. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914.